A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s Disease (NCT04994483)
RETHINK-ALZ
This trial is Currently recruiting
Registration number NCT04994483
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principle investigator
Associate Professor David Darby
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.